NASDAQ:OPK

OPKO Health (OPK) Stock Forecast, Price & News

$1.62

0.00 (0.00%)

(As of 09/22/2023 ET)

Compare

Today's Range: $1.60
▼
$1.65
50-Day Range: $1.62
▼
$2.17
52-Week Range: $1.00
▼
$2.24

Volume: 3.91 million shs
Average Volume: 2.19 million shs
Market Capitalization: $1.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.85

OPKO Health MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 137.7% Upside
$3.85 Price Target
Short Interest: Bearish
8.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1.82 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.20) to ($0.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

245th out of 965 stocks

Pharmaceutical Preparations Industry

100th out of 454 stocks

3.5

Analyst's Opinion

Consensus Rating
OPKO Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.85, OPKO Health has a forecasted upside of 137.7% from its current price of $1.62.
Amount of Analyst Coverage
OPKO Health has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.28% of the float of OPKO Health has been sold short.
Short Interest Ratio / Days to Cover
OPKO Health has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in OPKO Health has recently increased by 2.35%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
OPKO Health does not currently pay a dividend.
Dividend Growth
OPKO Health does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OPKO Health has received a 66.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Calcifediol", "Diagnostic test kits", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for OPKO Health is -1.65.

3.2

News and Social Media Coverage

News Sentiment
OPKO Health has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for OPKO Health this week, compared to 3 articles on an average week.
Search Interest
Only 22 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.
MarketBeat Follows
7 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OPKO Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,816,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
42.62% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 22.03% of the stock of OPKO Health is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OPKO Health are expected to decrease in the coming year, from ($0.20) to ($0.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OPKO Health is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OPKO Health is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OPKO Health has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Price History

30 days | 90 days | 365 days | Advanced Chart

OPK Stock News Headlines

September 20, 2023 | finance.yahoo.com

With 43% ownership, insiders at OPKO Health, Inc. (NASDAQ:OPK) are pretty optimistic and have been buying recently

September 12, 2023 | markets.businessinsider.com

Entera Collaborates With OPKO To Develop Oral Peptide Tablets For Obesity, Intestinal Malabsorption

September 23, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 12, 2023 | finance.yahoo.com

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

September 9, 2023 | thestreet.com

OPKO Health (OPK) Stock Falling After Bio-Reference Labs Acquisition

August 31, 2023 | benzinga.com

Esoteric Testing Market Poised to Touch $36.3 Billion by 2026- Exclusive Report by MarketsandMarkets™

August 8, 2023 | finance.yahoo.com

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

August 7, 2023 | markets.businessinsider.com

Opko Health (OPK) Receives a Buy from H.C. Wainwright

September 23, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

August 4, 2023 | markets.businessinsider.com

Barrington Reaffirms Their Buy Rating on Opko Health (OPK)

August 4, 2023 | finance.yahoo.com

Opko Health (OPK) Q2 2023 Earnings Call Transcript

August 3, 2023 | finance.yahoo.com

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2023 | msn.com

OPKO Health GAAP EPS of -$0.03 beats by $0.04, revenue of $265.4M beats by $63.43M

August 3, 2023 | finance.yahoo.com

OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

August 2, 2023 | benzinga.com

A Preview Of OPKO Health's Earnings

July 31, 2023 | msn.com

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

July 25, 2023 | finance.yahoo.com

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

July 23, 2023 | finance.yahoo.com

OPKO Health (NASDAQ:OPK) investors are sitting on a loss of 61% if they invested three years ago

July 6, 2023 | msn.com

Opko Health (OPK) Price Target Increased by 12.12% to 4.40

July 5, 2023 | fool.com

Opko Health (NASDAQ: OPK)

June 30, 2023 | benzinga.com

Opko Health shares are trading higher. Barrington Research recently upgraded the stock form Market Perform to Outperform.

June 30, 2023 | msn.com

The Great Market Miscalculation: Pfizer's True Value Remains Untapped

June 29, 2023 | benzinga.com

Opko Health shares are trading higher after Barrington Research upgraded the stock from Market Perform to Outperform and announced a $2 price target.

June 29, 2023 | benzinga.com

Barrington Research Upgrades OPKO Health to Outperform, Announces $2 Price Target

June 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Simulations Plus (SLP)

June 29, 2023 | finance.yahoo.com

Disney downgraded, Micron upgraded: Wall Street's top analyst calls

June 29, 2023 | msn.com

Biggest stock movers today: Pinterest, OPKO Health, AST SpaceMobile and more

See More Headlines

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Company Calendar

Last Earnings: 8/03/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:OPK
CUSIP: 68375N10
CIK: 944809
Web: www.opko.com
Phone: (305) 575-4100
Fax: 305-575-6015
Employees: 4,196
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.85
High Stock Price Forecast: $5.40
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +137.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-328,400,000.00
Net Margins: -24.10%
Pretax Margin: -30.18%
Return on Equity: -13.33%
Return on Assets: -9.60%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 1.92
Quick Ratio: 1.59

Sales & Book Value

Annual Sales: $1.00 billion
Price / Sales: 1.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.02 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 773,060,000
Free Float: 443,580,000
Market Cap: $1.25 billion
Optionable: Optionable
Beta: 1.76

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Phillip Frost Ph.D. (Age 87)
Chairman & CEO
Comp: $972.2k

Dr. Jane H. Hsiao M.B.A. (Age 76)
MBA, Ph.D., Vice Chairman & Chief Technical Officer
Comp: $912.2k

Dr. Elias Adam Zerhouni M.D. (Age 72)
Pres & Vice Chairman
Comp: $1.41M

Mr. Adam E. Logal (Age 45)
Sr. VP, CFO, Chief Accounting Officer & Treasurer
Comp: $712.2k

Mr. Steven D. Rubin Esq. (Age 63)
J.D., Exec. VP of Admin. & Director
Comp: $822.2k

Dr. Akhtar Ashfaq
Sr. VP of Clinical R&D and Medical Affairs

Ms. Jane Pine Wood Esq. (Age 61)
J.D., Chief Legal Officer of Bio-Reference Laboratories

Dr. Gary J. Nabel M.D. (Age 69)
Ph.D., Chief Innovation Officer & Director

Dr. David Okrongly Ph.D. (Age 64)
Pres of OPKO Diagnostics

Dr. Charles W. Bishop (Age 71)
Chief Exec. Officer of OPKO Renal

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPK Stock - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.
What is OPKO Health's stock price forecast for 2023?: 2 Wall Street analysts have issued twelve-month price targets for OPKO Health's shares. Their OPK share price forecasts range from $2.00 to $5.40. On average, they anticipate the company's share price to reach $3.85 in the next twelve months. This suggests a possible upside of 137.7% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.
How have OPK shares performed in 2023?: OPKO Health's stock was trading at $1.25 at the start of the year. Since then, OPK shares have increased by 29.6% and is now trading at $1.62.
View the best growth stocks for 2023 here.
When is OPKO Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our OPK earnings forecast.
How were OPKO Health's earnings last quarter?: OPKO Health, Inc. (NASDAQ:OPK) issued its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The biotechnology company had revenue of $265.40 million for the quarter, compared to the consensus estimate of $201.97 million. OPKO Health had a negative trailing twelve-month return on equity of 13.33% and a negative net margin of 24.10%. The company's revenue for the quarter was down 14.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.04) earnings per share.
What ETFs hold OPKO Health's stock?: ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Nasdaq Future Gen 200 ETF (QQQS) and VanEck Israel ETF (ISRA).iShares U.S. Healthcare Providers ETF (IHF).
What is Philip Frost's approval rating as OPKO Health's CEO?: 21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).
What is OPKO Health's stock symbol?: OPKO Health trades on the NASDAQ under the ticker symbol "OPK."
Who are OPKO Health's major shareholders?: OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.53%), State Street Corp (1.18%), Geode Capital Management LLC (1.13%), Charles Schwab Investment Management Inc. (0.67%), Northern Trust Corp (0.58%) and Dimensional Fund Advisors LP (0.49%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost and Robert J Shovlin.
View institutional ownership trends.
How do I buy shares of OPKO Health?: Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OPKO Health's stock price today?: One share of OPK stock can currently be purchased for approximately $1.62.
How much money does OPKO Health make?: OPKO Health (NASDAQ:OPK) has a market capitalization of $1.25 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $-328,400,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.
How many employees does OPKO Health have?: The company employs 4,196 workers across the globe.
How can I contact OPKO Health?: OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial